Yangge Biotech

Yangge Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of adeno-associated virus (AAV) mediated gene therapies. The company primarily focuses on addressing rare genetic disorders and ophthalmic conditions, leveraging its expertise in vector design and optimization. Its lead program, YG-001, is currently in clinical development for the treatment of Leber Hereditary Optic Neuropathy (LHON) associated with ND4 mutations. Yangge Biotech continues to expand its pipeline with several pre-clinical programs targeting various inherited retinal diseases and other genetic conditions. The firm aims to provide curative solutions for patients with limited treatment options through its proprietary AAV technology platform.